cladribine has been researched along with Liver Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baytas, SN; Cetin Atalay, R; Eren, F; Hawash, MM; Kahraman, DC | 1 |
| Apter, S; Davidson, T; Farfel, Z; Kneller, A; Sahar, N; Schiby, G | 1 |
| Bauer, F; Beham-Schmid, C; Brezinschek, R; Jaeger, G; Mannhalter, C; Neumeister, P | 1 |
| Geisen, FH; Graziadei, I; Kelly, T; Konwalinka, G; Schirmer, M; Vogel, W | 1 |
4 other study(ies) available for cladribine and Liver Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Chalcone; G2 Phase; Humans; Liver Neoplasms; Pyrazoles; Structure-Activity Relationship | 2017 |
Hairy cell leukemia presenting as multiple discrete hepatic lesions.
Topics: Antineoplastic Agents; Cladribine; Diagnosis, Differential; Humans; Leukemia, Hairy Cell; Liver; Liver Neoplasms; Male; Middle Aged; Organ Size; Treatment Outcome | 2009 |
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Topics: Adult; Alemtuzumab; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Transfusion; Cladribine; Cyclophosphamide; Doxorubicin; Female; Humans; Liver Neoplasms; Lymphoma, T-Cell; Neutropenia; Prednisolone; Receptors, Antigen, T-Cell, gamma-delta; Recurrence; Remission Induction; Rituximab; Splenic Neoplasms; Vincristine | 2008 |
Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cladribine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Liver Neoplasms; Nucleosides; Tumor Cells, Cultured | 1998 |